ELATE

Background

Randomized, double-blind trial (ELATE). 738 patients with unprovoked proximal DVT or PE who had completed ≥3 months of warfarin therapy. Randomized to conventional-intensity warfarin (target INR 2.0–3.0) or low-intensity warfarin (target INR 1.5–1.9) for a mean 2.4 years. This trial directly compared the two intensity strategies head-to-head, motivated by the concern that conventional warfarin carries bleeding risk that might be reducible with a lower INR target while maintaining efficacy. The PREVENT trial (Ridker, NEJM 2003) had shown low-intensity warfarin was superior to placebo, but ELATE asked whether low-intensity was non-inferior to conventional therapy.

Interventions and follow up

Arm A: Conventional-intensity warfarin, target INR 2.0–3.0, long-term
Arm B: Low-intensity warfarin, target INR 1.5–1.9, long-term; both arms followed for mean 2.4 year
Primary endpoint: Symptomatic recurrent VTE
mFollow up: Mean 2.4 year

Results

Recurrent VTE: 0.7/100 pt-yrs (conventional) vs 1.9/100 pt-yrs (low-intensity), HR 2.8 (95% CI 1.1–7.0) favoring conventional — CONVENTIONAL SUPERIOR
Major bleeding: 0.9/100 pt-yrs (conventional) vs 1.1/100 pt-yrs (low), HR 1.2 (95% CI 0.4–3.0) — NOT significantly different
Any bleeding: HR 1.3 (95% CI 0.8–2.1) — not significantly different
Deaths: 5 conventional vs 9 low-intensity — not significantly different

Adverse events

Main adverse events: Major bleeding was low and similar between the two arms — the critical finding that disproved the hypothesis that lower INR reduces bleeding. Both arms had comparable rates of overall adverse events. The INR monitoring burden was similar in both arms despite the lower target range.

Conclusions

Conventional-intensity warfarin (INR 2.0–3.0) is significantly more effective than low-intensity warfarin (INR 1.5–1.9) for secondary VTE prevention, with no significant difference in major bleeding, demonstrating that reducing the INR target below 2.0 is not an acceptable strategy for extended VTE treatment.

Key Limitations

Key Limitations: Open to the ethical concern of treating both arms with active anticoagulation rather than including a placebo arm (PREVENT provided that comparison). Low-intensity INR 1.5–1.9 — the comparator — may have been sub-therapeutic for VTE prevention by design; this warrants the question of whether the comparison is clinically relevant. Patients with APS, active cancer, or severe thrombophilia were not separately analyzed. Results not directly applicable to DOAC use, where the concept of "dose intensity" is defined differently (treatment dose vs reduced extended-phase dose). The lack of increased bleeding with conventional vs low-intensity was unexpected and runs counter to the initial hypothesis.

Clinical Context

ELATE, together with PREVENT, definitively established that extended anticoagulation at full-intensity VKA (INR 2.0–3.0) is the optimal warfarin strategy — not low-intensity — and that bleeding risk is not significantly reduced by targeting a lower INR. This principle has been carried into the DOAC era: extended-phase reduced DOAC dosing (rivaroxaban 10 mg, apixaban 2.5 mg BID) was designed not to simply lower drug exposure but to maintain antithrombotic efficacy at a dose that does not increase bleeding. ELATE also reinforced that the INR 2.0–3.0 target should not be lowered to reduce bleeding risk in VTE patients without clear indication.

References

References: Kearon C et al, NEJM 2003 (ELATE primary)